FDA approves GSK's nonadjuvant H1N1 vaccine
GlaxoSmithKline gained FDA approval for a modified version of its seasonal flu vaccine FluLaval that has no adjuvant and contains the H1N1 strain. The company expects to begin distributing the vaccine in December and satisfy an order of 7.6 million doses from the government.
Bloomberg
| 11/10
This story published in FMI Pharmacy dailyLead on 11/16/2009
Get stories like these delivered daily for FREE:
|
FMI Pharmacy dailyLead
Designed specifically for pharmacy professionals, FMI Pharmacy dailyLead is a FREE, daily e-mail newsletter. It provides the latest news in the pharmacy arena. Learn more |
|